Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. November 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018

DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it...
27. Oktober 2018 13:00 ET | Quelle: Chimerix, Inc.

Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018

Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C., Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced...
11. Oktober 2018 16:01 ET | Quelle: Chimerix, Inc.

Chimerix to Host Annual Investor Update on October 17, 2018

DURHAM, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the...
05. Oktober 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek

DURHAM, N.C., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the...
04. Oktober 2018 07:00 ET | Quelle: Chimerix, Inc.

Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

DURHAM, N.C., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the full analysis of...
26. September 2018 07:30 ET | Quelle: Chimerix, Inc.

Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference

DURHAM, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle...
29. August 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix to Participate in September Investor Conferences

DURHAM, N.C., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that company...
08. August 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix Announces Second Quarter 2018 Financial Results

DURHAM, N.C., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and...
01. August 2018 08:00 ET | Quelle: Chimerix, Inc.

Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018

DURHAM, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a...
12. Juni 2018 07:00 ET | Quelle: Chimerix, Inc.

Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus

- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C., June 12, 2018 (GLOBE NEWSWIRE) --...

Vorherige Seite

Nächste Seite